SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Aurobindo’s hypertension drug gets USFDA nod

13 Jun 2011 Evaluate

Aurobindo Pharma has received final approval from the US health regulator to market and manufacture Ramipril Capsules, used for treating hypertension, in the American market. The company has received approval from the USFDA for Ramipril Capsules in strengths of 1.25 mg, 2.5 mg, 5 mg and 10 mg. The product has a market size of approximately USD 95 million for the twelve months ending September 2010 according to IMS and will be launched soon.  Ramipril Capsules, which are the generic equivalent of King Pharmaceuticals Altace, are indicated for the treatment of hypertension and falls under the cardiovascular therapeutic segment.crackcrack

Aurobindo Pharma Share Price

1548.85 -6.10 (-0.39%)
29-Jun-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1872.60
Dr. Reddys Labs. 1376.30
Cipla 1453.50
Zydus Lifesciences 1121.65
Lupin 2407.45
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: